Condition: Biliary Tract Neoplasms · Cholangiocarcinoma, Intrahepatic · Cholangiocarcinoma, Extrahepatic · Sponsor: Shanghai Zhongshan Hospital
BTC-Ag-T (ACH-AgT001) is an autologous experimental T-cell therapy designed for advanced biliary tract cancer. This is an open-label, single-arm Phase 1 study to evaluate the safety, tolerability, and preliminary efficacy of BTC-Ag-T in patients with advanced, unresectable, or metastatic biliary tract cancer who have failed standard-of-care therapy.
This description comes directly from the study's public registry record.
Guoming Shi, MD, PhD · +86 021-64041990 · shi.guoming@zs-hospital.sh.cn
Always discuss trial participation with your own doctor first.
| Shanghai Zhongshan Hospital, Fudan University | Shanghai, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07614061